Alzamend Neuro, Inc.ALZNNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank56
3Y CAGR-35.2%
5Y CAGR+5.8%
Year-over-Year Change
Research and development spending
3Y CAGR
-35.2%/yr
vs +100.3%/yr prior
5Y CAGR
+5.8%/yr
Recent deceleration
Acceleration
-135.5pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $1.41M | -78.1% |
| 2024 | $6.46M | -13.3% |
| 2023 | $7.45M | +43.2% |
| 2022 | $5.20M | +296.7% |
| 2021 | $1.31M | +22.6% |
| 2020 | $1.07M | -71.1% |
| 2019 | $3.70M | +1044.1% |
| 2018 | $323403.00 | +17.6% |
| 2017 | $275047.00 | - |
| 2016 | $0.00 | - |